Gilead Sciences Inc (GILD): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Gilead ( GILD) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.8%. By the end of trading, Gilead rose $1.54 (3.0%) to $52.89 on average volume. Throughout the day, 12,536,909 shares of Gilead exchanged hands as compared to its average daily volume of 12,279,000 shares. The stock ranged in a price between $51.81-$53.41 after having opened the day at $51.88 as compared to the previous trading day's close of $51.35. Other companies within the Drugs industry that increased today were: Prothena Corporation ( PRTA), up 13.8%, Vanda Pharmaceuticals ( VNDA), up 9.5%, Ariad Pharmaceuticals ( ARIA), up 9.2% and NewLink Genetics ( NLNK), up 9.0%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $76.5 billion and is part of the health care sector. The company has a P/E ratio of 29.2, above the S&P 500 P/E ratio of 17.7. Shares are up 36.5% year to date as of the close of trading on Thursday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, solid stock price performance, reasonable valuation levels and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, China Biologic Products ( CBPO), down 12.9%, Prima Biomed ( PBMD), down 10.2%, Skystar Bio-Pharmaceutical Company ( SKBI), down 10.1% and Oxygen Biotherapeutics ( OXBT), down 9.9% , were all laggards within the drugs industry with MannKind Corporation ( MNKD) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.